Violation Tracker Individual Record
Company:Janssen Pharmaceuticals, Inc.
Date:January 3, 2013
Offense Group:healthcare-related offenses
Primary Offense:off-label or unapproved promotion of medical products
Janssen Pharmaceuticals pleaded guilty to a charge of introducing a misbranded drug, Risperdal, into interstate commerce and was ordered to pay a $344 million fine and forfeiture of $66 million.
Level of Government:federal
Action Type:agency action
Agency:U.S. Attorney-Eastern District of Pennsylvania
Civil or Criminal Case:criminal
HQ Country of Parent:USA
HQ State of Parent:New Jersey
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source of Data:
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.